FDA Proposes Eight-Month Review of Priority Generics, Plans for Wave of Biosimilars By Anna Jurczynska | March 13, 2017 Posted in Recent News and tagged biosimilars, FDA, GDUFA II, generic, second generation of user fee agreements, U.S. ← U.S., E.U. Agree on Mutual Recognition of Drug Manufacturing InspectionsFDA Drug Trials Snapshots and Diversity When Testing New Drugs →